2014 has seen four new directions in which research into non-small cell lung cancer can go. This is a huge achievement. Non- small cell lung cancer is the most common type of lung cancer- about 85% of all lung cancer cases fall under this category. Epidermal Growth Factor Receptor (EGFR) is found in about 30% of the non-small cell lung cancer cases. The new directions discovered deal with EGFR, and how EGFR cancer can be treated. The research hopes to make the existing treatment more responsive, and tries to find new drug therapies.
The four new directions in EGFR research are the following:
- Studying how to overcome acquired resistance to EGFR treatments based on tyrosine kinase inhibitors.
- Studying why there is resistance to TKI medication used in EGFR lung cancer treatments.
- Epidemiology of Lung Cancer (EGFR type)
- Transformation to short cell lung cancer in TKI resistance
It is expected that these new directions would explore current and new medication for non-small cell lung cancer. This is groundbreaking work, for it would certainly help us understand exactly what makes non-small cell lung cancer happen and how one can cure it definitely. The study does focus on EGFR type- but the EGFR type has a significantly large presence. This study does not just try to determine the epidemiology of the cancer, it also tries to find out why some people are resistant to some diseasess. This knowledge can be of great importance in the future. These new pathways can lead to some promising treatments in the near future.